Article

Acquired <i>RAD51C</i> promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

2020-12-11

Abstract excerpt

<h4>ABSTRACT</h4> While loss of BRCA1 promoter methylation has been shown to cause PARP inhibitor (PARPi) resistance in high-grade serous ovarian carcinoma (HGSC), the impacts of RAD51C methylation (me RAD51C ) remain unresolved. In this study, three PARPi-responsive HGSC patient-derived xenografts (PDX) with RAD51C gene silencing and homologous recombination deficiency were found to have either homogeneous o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c53da66f-f2db-508f-8219-e54c74e8482d
DOI: 10.1101/2020.12.10.419176

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Acquired <i>RAD51C</i> promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinomaDOI 10.1101/2020.12.10.419176Read

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaSemantic proximity Read

Characterization of a <i>RAD51C</i> -Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance DevelopmentSemantic proximity Read

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceSemantic proximity Read

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaSemantic proximity Read

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read

Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinomaSemantic proximity Read

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencingSemantic proximity Read

Homologous Recombination Proficiency in High-Grade Serous Epithelial Ovarian Cancer Tumors: The Dark Side of the MoonSemantic proximity Read

Mechanisms of PARP inhibitor resistance in ovarian cancerSemantic proximity Read

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinomaSemantic proximity Read

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challengesSemantic proximity Read